QURE

uniQureA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-16

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$36.00

+33.4% vs current

Most likely

Base case

50%

Probability

Target price

$30.00

+11.2% vs current

B-

Bear case

25%

Probability

Target price

$20.00

-25.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-15

AI commentary

Tone remains cautiously constructive but monitoring-oriented rather than fully bullish. The primary May 5 company update confirmed milestone timing and a long cash runway, and QURE closed at $27.75 on May 14, 2026 with shares at $27.22 intraday on May 15, 2026, suggesting the post-print reaction has not collapsed. Still, delayed analyst-revision evidence is sparse, consensus/revenue-surprise reporting is mostly from secondary earnings pages, and low coverage means the stock can stay volatile around each AMT-130 and AMT-260 headline.

RankAlpha Sentiment Codex - 2026-05-15

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-20catalystPost-earnings digestion tests whether Q1 updates can hold the stock above pre-print levelsHigh impact

The May 5 earnings update kept the core AMT-130, AMT-260 and cash-runway milestones intact, with $586.6 million of cash, cash equivalents and current investment securities and runway into the second half of 2029, while Q1 revenue was $3.6 million and net loss was $53.5 million [#8-K-2026-05-05] [#10-Q-2026-05-05]. Secondary post-print coverage is thin; one checked earnings page showed a modest EPS beat versus consensus but a revenue miss, and delayed analyst revision evidence remained sparse, so near-term sentiment likely depends on whether investors focus on runway and milestone cadence rather than the still-lossmaking profile.

2026-06-18eventAMT-260 first-cohort epilepsy update at the Epilepsy Foundation Pipeline ConferenceHigh impact

uniQure said it expects to present Phase I/IIa data from the first six AMT-260 patients with up to six months of follow-up at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026, giving investors a nearer-term clinical readout outside Huntington's disease [#8-K-2026-05-05].

2026-06-30eventAMT-130 regulatory path clarity from FDA Type B meeting and UK filing trackHigh impact

Management said a Type B FDA meeting is scheduled for Q2 2026 to discuss a potential new AMT-130 trial design and the statistical analysis plan for the four-year data expected in Q3 2026, while a UK MAA remains on track for Q3 2026 after a constructive MHRA pre-submission meeting [#8-K-2026-05-05] [#10-Q-2026-05-05]. This remains the highest-value catalyst because U.S. approval evidence requirements are still unsettled.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-15 • Updated nightlySource: Internal modelMethodology